孤立性浅静脉血栓在真实世界条件下的管理与结局(INSIGHTS-SVT)
主要复合结局发生率为5.8%,其中复发或延伸性SVT 4.7%、深静脉血栓1.7%、肺栓塞0.8%;磺达肝癸钠相比低分子肝素的主要结局风险更低(4.4% vs. 9.6%;HR 0.51;95%CI 0.3-0.9;
要点
- 孤立性SVT患者3个月内仍有血栓栓塞并发症风险,主要为SVT复发或延伸。
- 真实世界中约三分之一患者使用肝素类、口服抗凝药或未抗凝。
- 磺达肝癸钠的主要结局风险低于低分子肝素(HR 0.51;95%CI 0.3-0.9)。
核心结论
- 孤立性SVT患者3个月随访期间存在血栓栓塞并发症风险,尽管接受了抗凝治疗。
主要发现
- 主要复合结局(症状性DVT、PE及SVT延伸或复发)发生率为5.8%,其中SVT复发或延伸4.7%、DVT 1.7%、PE 0.8%。
- 临床相关非大出血发生率为1.2%,大出血为0.3%;完全临床恢复者708例(62.4%)。
- 多变量分析中与主要结局相关的因素包括既往SVT史(HR 2.3)、年龄每岁(HR 0.97)、药物治疗持续时间每周(HR 0.92)和血栓长度(HR 1.03)。
关键数值与推荐
- 基线时93.6%接受药物治疗(磺达肝癸钠65.7%、肝素类23.2%、直接口服抗凝药4.3%、镇痛药14.5%),77.0%接受压力治疗,1.9%接受手术,6.4%未接受任何抗凝治疗。
- SVT位于膝下者54.5%,膝上者26.7%,膝上及膝下者18.8%。
临床怎么用
- 真实世界中孤立性SVT的抗凝选择差异较大,磺达肝癸钠可能与较低的主要结局风险相关。
- 应关注既往SVT史、血栓长度等与不良结局相关的因素,并规范抗凝疗程。
局限性
- 本文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. METHODS: Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. RESULTS: A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was below the knee in 54.5%, above the knee in 26.7%, above and below the knee in 18.8%. At baseline, 93.6% received pharmacological treatment (65.7% fondaparinux, 23.2% heparins, 4.3% direct oral anticoagulants [DOACs], 14.5% analgesics), 77.0% compression treatment, and 1.9% surgery; 6.4% did not receive any anticoagulation. The primary outcome occurred in 5.8%; 4.7% had recurrent or extended SVT, 1.7% DVT, and 0.8% PE. Clinically relevant non-major bleeding occurred in 1.2% and major bleeding in 0.3%. Complete clinical recovery of SVT was reported in 708 patients (62.4%). Primary outcome adjusted by propensity score and for treatment duration was lower with fondaparinux compared with low molecular weight heparin (4.4% vs. 9.6%; hazard ratio [HR] 0.51; 95% confidence interval [CI] 0.3 - 0.9; p = .017). On multivariable analysis, associated factors for primary outcome included another SVT prior to the present SVT event (HR 2.3), age per year (HR 0.97), duration of drug treatment per week (HR 0.92), and thrombus length (HR 1.03). CONCLUSION: At three month follow up, patients with isolated SVT are at risk of thromboembolic complications (mainly recurrent or extended SVT), despite anticoagulation. In this real life study, about one third had received either heparins, oral anticoagulants, or no anticoagulation.
引用
- Bauersachs R, Gerlach HE, Heinken A, et al. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg. 2021. PMID: 34210599. doi:10.1016/j.ejvs.2021.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。